The Latest Advances in Lung Cancer Research: From Basic Science to Therapeutics

March 12-14, 2007
Hotel Grand Court, Nagoya, Japan

Organizing Committee:

JCA:

Takashi Takahashi, Nagoya University, Nagoya, Japan (Co-Chairperson)
Jun Yokota, National Cancer Center Research Institute, Tokyo, Japan
Saburo Sone, University of Tokushima, Tokushima, Japan

AACR:

Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA (Co-Chairperson)
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA
Jill M. Siegfried, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Show Details

March 12 ( Monday)

Opening Remarks (12:50 pm - 1:00 pm)
Keynote addresses (1:00 pm - 2:30 pm)

1. Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD, USA
   T.B.A
2. Kazuo Tajima, Aichi Cancer Center Research Institute, Nagoya, Japan
   Epidemic Pattern of Asian Lung Cancer and Its Causal Factors

Animal models session (2:30 pm - 4:00 pm)

1. Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA, USA
   Mouse Models of Lung Cancer
2. Gang-Hong Lee, Kochi Medical School, Kochi, Japan
   Genetic Control of the Lung Tumor Resistance of BALB/c Mice
3. Seiji Yano, University of Tokushima Graduate School of Medical Sciences, Tokushima, Japan
   Patient-Like Metastasis Models for Lung Cancer

Poster Session A & Mixer (4:00 pm - 7:30 pm)

Pathobiology of lung adenocarcinomas (7:30 pm ? 9:30 pm)

1. Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA
   The Impact of EGFR Mutations on Adenocarcinoma of the Lung
2. William D. Travis, Armed Forces Institute of Pathology, Washington, DC, USA
   Histologic Correlation with Molecular Changes in Lung Adenocarcinoma
3. Yuichi Ishikawa, Cancer Institute, Tokyo, Japan
   Classification of Lung Cancer by Gene Expression Profiling
4. Mayumi Ono, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
   Epidermal Growth Factor Receptor (EGFR) Driven Activation in Association with Responses to EGFR Targeting Drugs

Poster Session A

March 13 (Tuesday)

Genetics and Epigenetics (8:30 am - 10:30 am)

1. Steven A. Belinsky, Lovelace Respiratory Research Institute, Albuquerque, NM, USA
   Carcinogen-induced Gene Promoter Hypermethylation and Transformation of Bronchial Epithelial Cells
2. Izuho Hatada, Institute for Molecular & Cellular Regulation, Gunma University, Gunma, Japan
   Microarray-Based Genome-Wide DNA Methylation Analysis
3. Yoshinori Murakami, National Cancer Center Research Institute, Tokyo, Japan
   Involvement of a Tumor Suppressor TSLC1 in Lung Carcinogenesis
4. James G. Herman, Johns Hopkins University School of Medicine, Baltimore, MD, USA
   T.B.A

Coffee Break (10:30 am - 11:00 am)

Genomics, proteomics and biomarkers 1 (11:00 am - 12:30 pm)

1. Malcolm V. Brock, Johns Hopkins School of Medicine, Baltimore, MD, USA
   Using DNA Methylation Markers to Predict Early Recurrence and to Re-Stage Patients with Stage 1 Lung Cancer
2. Yataro Daigo, Institute of Medical Science, University of Tokyo, Tokyo, Japan
   From Cancer Genomics to the Cancer Clinic:Novel Biomarker Discovery for Lung Cancer Diagnostics and Therapeutics
3. Tadashi Kondo, National Cancer Center Research Institute, Tokyo, Japan
   Lung Cancer Proteomics

Lunch (12:30 pm - 1:30 pm)

Genomics, proteomics and biomarkers 2 (1:30 pm - 3:30 pm)

1. William L. Bigbee, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
   Proteomic and Metabolomic Biomarker Discovery for Lung Cancer Detection and Prognosis
2. Shuta Tomida, Nagoya University Graduate School of Medicine, Nagoya, Japan
   T.B.A
3. Kazuto Nishio, Kinki University School of Medicine, Osaka, Japan
   Biomarker Studies in Clinical Studies for Target Based Drugs in Japan
4. David G. Beer, University of Michigan Medical School, Ann Arbor, USA
   Gene Expression Analyses of Lung Cancer to Identify Processes Influencing Patient Survival

Poster Session B (3:30 pm - 6:00 pm)

Dinner (6:30 pm - 8:30 pm)

March 14 (Wednesdays)

Epidemiology and Prevention (8:30 am - 10:00 am)

1. Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
   Inflammation in the Pathogenesis of Lung Cancer: Defining Novel Targets for Prevention
2. Takashi Kohno, National Cancer Center Research Institute, Tokyo, Japan
   DNA Repair and Other Genes Involved in Lung Cancer Susceptibility
3. Xifeng Wu, UT MD Anderson Cancer Center, Houston, TX, USA
   Genetic Predisposition to Lung Cancer: From Risk to Clinical Outcome

Coffee Break (10:00 am - 10:30 am)

Novel therapeutic approaches (10:30 am - 1:00 pm)

1. Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY, USA
   Inhibition of Map Kinase Signaling For Lung Cancer Therapy
2. Richard J. Pietras, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
   Targeting Estrogen and Growth Factor Signaling in Human Non-small Cell Lung Cancer
3. Ravi Salgia, University of Chicago Hospital, Chicago, IL, USA
   Role of c-Met in upper aerodigestive malignancies
4. Hirotaka Osada, Aichi Cancer Center Research Institute, Nagoya, Japan
   The ASH1 Gene may be a Prototypic “Lineage-Survival Oncogene” and a Specific the Rapeutic Target for Lung Cancers with Neuroendocrine Features
5. Nobutaka Fujii, Graduate School of Pharmaceutical Sciences, Kyoto University , Kyoto, Japan
   CXCR4 Antagonists: Relevance to Small Cell Lung Cancer Chemotherapy

Closing Remarks　(1:00 pm - 1:10 pm)